WiseGuyReports.Com Publish a New
Market Research Report On –“HIV / AIDS Therapeutics Companies And Drugs
Pipeline Review 2016”.
COMPLETE
REPORT DETAILS @
https://www.wiseguyreports.com/reports/590076-hiv-aids-pipeline-review-h1-2016
The, ‘HIV / AIDS - Pipeline Review, H1 2016’,
provides an overview of the HIV / AIDS pipeline landscape.
The report provides comprehensive information on the
therapeutics under development for HIV / AIDS, complete with analysis by stage
of development, drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type. The report also covers the descriptive pharmacological
action of the therapeutics, its complete research and development history and
latest news and press releases. Additionally, the report provides an overview
of key players involved in therapeutic development for HIV / AIDS and features
dormant and discontinued projects.
For more information or any query mail at sales@wiseguyreports.com
The report features investigational drugs from
across globe covering over 20 therapy areas and nearly 3,000 indications. The
report is built using data and information sourced from Global Markets Direct’s
proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
Note*: Certain sections in the report may be removed
or altered based on the availability and relevance of data.
GET
A SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/590076-hiv-aids-pipeline-review-h1-2016
Scope
- The report provides
a snapshot of the global therapeutic landscape of HIV / AIDS
- The report reviews pipeline therapeutics for HIV / AIDS by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved HIV / AIDS therapeutics and enlists all their major and minor projects
- The report assesses HIV / AIDS therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for HIV / AIDS
- The report reviews pipeline therapeutics for HIV / AIDS by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved HIV / AIDS therapeutics and enlists all their major and minor projects
- The report assesses HIV / AIDS therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for HIV / AIDS
Reasons to buy
- Gain strategically
significant competitor information, analysis, and insights to formulate
effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for HIV / AIDS
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding HIV / AIDS pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for HIV / AIDS
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding HIV / AIDS pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents – Key Points
Introduction
9
HIV / AIDS Overview 10
Therapeutics Development 11
HIV / AIDS - Therapeutics under Development by Companies 13
HIV / AIDS - Therapeutics under Investigation by Universities/Institutes 25
HIV / AIDS - Pipeline Products Glance 31
HIV / AIDS - Products under Development by Companies 35
HIV / AIDS - Products under Investigation by Universities/Institutes 53
HIV / AIDS - Companies Involved in Therapeutics Development 62
HIV / AIDS - Therapeutics Assessment 194
Drug Profiles 211
HIV / AIDS - Dormant Projects 779
HIV / AIDS - Discontinued Products 824
HIV / AIDS - Product Development Milestones 831
Appendix 843
HIV / AIDS Overview 10
Therapeutics Development 11
HIV / AIDS - Therapeutics under Development by Companies 13
HIV / AIDS - Therapeutics under Investigation by Universities/Institutes 25
HIV / AIDS - Pipeline Products Glance 31
HIV / AIDS - Products under Development by Companies 35
HIV / AIDS - Products under Investigation by Universities/Institutes 53
HIV / AIDS - Companies Involved in Therapeutics Development 62
HIV / AIDS - Therapeutics Assessment 194
Drug Profiles 211
HIV / AIDS - Dormant Projects 779
HIV / AIDS - Discontinued Products 824
HIV / AIDS - Product Development Milestones 831
Appendix 843
List of Tables
Number of Products under Development for HIV / AIDS, H1 2016 53
Number of Products under Development for HIV / AIDS - Comparative Analysis, H1 2016 54
Number of Products under Development by Companies, H1 2016 56
Number of Products under Development by Companies, H1 2016 (Contd..1) 57
Number of Products under Development by Companies, H1 2016 (Contd..2) 58
Number of Products under Development by Companies, H1 2016 (Contd..3) 59
Number of Products under Development by Companies, H1 2016 (Contd..4) 60
Number of Products under Development by Companies, H1 2016 (Contd..5) 61
Number of Products under Development by Companies, H1 2016 (Contd..6) 62
Number of Products under Development by Companies, H1 2016 (Contd..7) 63
Number of Products under Development by Companies, H1 2016 (Contd..8) 64
Number of Products under Development by Companies, H1 2016 (Contd..9) 65
Number of Products under Development by Companies, H1 2016 (Contd..10) 66
Number of Products under Investigation by Universities/Institutes, H1 2016 67
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 68
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 69
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 70
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 71
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 72
Comparative Analysis by Late Stage Development, H1 2016 73
Comparative Analysis by Clinical Stage Development, H1 2016 74
Comparative Analysis by Early Stage Development, H1 2016 75
Comparative Analysis by Unknown Stage Development, H1 2016 76
Products under Development by Companies, H1 2016 77
Products under Development by Companies, H1 2016 (Contd..1) 78
Products under Development by Companies, H1 2016 (Contd..2) 79
Products under Development by Companies, H1 2016 (Contd..3) 80
Products under Development by Companies, H1 2016 (Contd..4) 81
Products under Development by Companies, H1 2016 (Contd..5) 82
Products under Development by Companies, H1 2016 (Contd..6) 83
Products under Development by Companies, H1 2016 (Contd..7) 84
Products under Development by Companies, H1 2016 (Contd..8) 85
Products under Development by Companies, H1 2016 (Contd..9) 86
Products under Development by Companies, H1 2016 (Contd..10) 87
Products under Development by Companies, H1 2016 (Contd..11) 88
Products under Development by Companies, H1 2016 (Contd..12) 89
Products under Development by Companies, H1 2016 (Contd..13) 90
Products under Development by Companies, H1 2016 (Contd..14) 91
Products under Development by Companies, H1 2016 (Contd..15) 92
Products under Development by Companies, H1 2016 (Contd..16) 93
Products under Development by Companies, H1 2016 (Contd..17) 94
Number of Products under Development for HIV / AIDS, H1 2016 53
Number of Products under Development for HIV / AIDS - Comparative Analysis, H1 2016 54
Number of Products under Development by Companies, H1 2016 56
Number of Products under Development by Companies, H1 2016 (Contd..1) 57
Number of Products under Development by Companies, H1 2016 (Contd..2) 58
Number of Products under Development by Companies, H1 2016 (Contd..3) 59
Number of Products under Development by Companies, H1 2016 (Contd..4) 60
Number of Products under Development by Companies, H1 2016 (Contd..5) 61
Number of Products under Development by Companies, H1 2016 (Contd..6) 62
Number of Products under Development by Companies, H1 2016 (Contd..7) 63
Number of Products under Development by Companies, H1 2016 (Contd..8) 64
Number of Products under Development by Companies, H1 2016 (Contd..9) 65
Number of Products under Development by Companies, H1 2016 (Contd..10) 66
Number of Products under Investigation by Universities/Institutes, H1 2016 67
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 68
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 69
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 70
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 71
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 72
Comparative Analysis by Late Stage Development, H1 2016 73
Comparative Analysis by Clinical Stage Development, H1 2016 74
Comparative Analysis by Early Stage Development, H1 2016 75
Comparative Analysis by Unknown Stage Development, H1 2016 76
Products under Development by Companies, H1 2016 77
Products under Development by Companies, H1 2016 (Contd..1) 78
Products under Development by Companies, H1 2016 (Contd..2) 79
Products under Development by Companies, H1 2016 (Contd..3) 80
Products under Development by Companies, H1 2016 (Contd..4) 81
Products under Development by Companies, H1 2016 (Contd..5) 82
Products under Development by Companies, H1 2016 (Contd..6) 83
Products under Development by Companies, H1 2016 (Contd..7) 84
Products under Development by Companies, H1 2016 (Contd..8) 85
Products under Development by Companies, H1 2016 (Contd..9) 86
Products under Development by Companies, H1 2016 (Contd..10) 87
Products under Development by Companies, H1 2016 (Contd..11) 88
Products under Development by Companies, H1 2016 (Contd..12) 89
Products under Development by Companies, H1 2016 (Contd..13) 90
Products under Development by Companies, H1 2016 (Contd..14) 91
Products under Development by Companies, H1 2016 (Contd..15) 92
Products under Development by Companies, H1 2016 (Contd..16) 93
Products under Development by Companies, H1 2016 (Contd..17) 94
Continue……
For more information or any query mail at
sales@wiseguyreports.com
CHECK DISCOUNT ON THIS REPORT @ https://www.wiseguyreports.com/check-discount/590076-hiv-aids-pipeline-review-h1-2016
Contact
Us:
NORAH TRENT
Partner
Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph:
+1-646-845-9349 (US)
Ph:
+44 208 133 9349 (UK)
No comments:
Post a Comment